No clinical data available. Affinity for several cytochromes, but studies show no relevant CYP inductive or inhibitory properties. Based on theoretical data the drug is classified as probably not porphyrinogenic. However side effects such as anorexia, reduced appetite, nausea and vomiting are common and may be potentially porphyrinogenic through reduction in caloric intake.

Centrally acting sympathomimetic. A selective and potent inhibitor of the pre-synaptic noradrenaline transporter. Adverse reactions that can mimic porphyria symptoms are abdominal pain, vomiting, nausea, irritability. These side effects may be potentially porphyrinogenic through reduction in caloric intake.

Report on uneventful use: One report of uneventful use of atomoxetine > 5 months in female AIP patient with known mutation. Porphyrin excretion low/normal during use. From Dr Salamanca, Madrid.

No clinical or experimental litterature concerning atomoxetine and acute porphyria could be found.